Results for &quot;&quot;Activin Receptors, Type II&quot;&quot;[mesh_terms]

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.

Sujit Sheth, Kevin H M Kuo, Maria Domenica Cappellini, Antonis Kattamis, Ali T Taher, Khaled M Musallam

Drug design, development and therapy 2023;17():1583-1591

Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.

John B Porter, Dimana Miteva, Jeevan K Shetty, Shien Guo, Peiwen Yu, Jennifer Lord-Bessen, Aylin Yucel, Derek Tang, Alexis A Thompson, Olivier Hermine, Tatiana Zinger, Ersi Voskaridou, Farrukh Shah, Antonio Piga, Maria Domenica Cappellini, Vip Viprakasit, Esther Natalie Olíva, Ellis J Neufeld, Ali T Taher, Jay T Backstrom

European journal of haematology 2023;111(1):113-124

Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.

Hadi Darvishi-Khezri, Hossein Karami

Advances in therapy 2021;38(4):1732-1745

Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.

John A Phillips, James E Loyd, John H Newman

Annals of internal medicine 2008;148(4):278-83

Luspatercept for β-thalassemia: beyond red blood cell transfusions.

Maria Domenica Cappellini, Ali T Taher

Expert opinion on biological therapy 2022;21(11):1363-1371

Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes.

Naseema Gangat, Ayalew Tefferi

American journal of hematology 2025;100 Suppl 4():51-65

Drug safety in thalassemia: lessons from the present and directions for the future.

Joseph Borg, Janet Sultana, Laura Grech, Karen Borg

Expert opinion on drug safety 2021;20(8):937-947

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.

Matteo Molica, Marco Rossi

Expert opinion on biological therapy 2024;24(4):233-241

The Role of Iron in Benign and Malignant Hematopoiesis.

Delfim Duarte, Stefano Rivella, Amaliris Guerra, Joana Pereira-Reis, Sayantani Sinha

Antioxidants & redox signaling 2022;35(6):415-432

Hereditary haemorrhagic telangiectasia.

Sabine Bailly, Omer F Eker, Marcelo Serra, Ruben Hermann, Claire L Shovlin, Elisabetta Buscarini, Raj S Kasthuri, Sophie Dupuis-Girod

Nature reviews. Disease primers 2025;11(1):1

A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.

Rebecca A Miksad, Ghassan K Abou-Alfa, Mohamedtaki A Tejani, Stephen Williamson, Martin E Gutierrez, Olugbenga O Olowokure, Manish R Sharma, Matthew L Sherman, Imane El Dika, Shuchi S Pandya

The oncologist 2020;24(2):161-e70

Muscle protein kinetics in cancer cachexia.

Neil Johns, Nathan A Stephens, Tom Preston

Current opinion in supportive and palliative care 2013;6(4):417-23

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.

Anna Mies, Olivier Hermine, Uwe Platzbecker

Current hematologic malignancy reports 2017;11(6):416-424

Genetic Variant in ACVR2B Is Associated with Lean Mass.

Yann C Klimentidis, Jennifer W Bea, Patricia Thompson, Walter T Klimecki, Chengcheng Hu, Guanglin Wu, J Skye Nicholas, Kelli K Ryckman, Zhao Chen

Medicine and science in sports and exercise 2017;48(7):1270-5